3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
8
Carcinoid Tumor
3
Acromegaly
3
Pituitary Neoplasms
2
Neoplasm Metastasis
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Hepatocellular
2
Pheochromocytoma
1
Paraganglioma
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Growth Hormone-Secreting Pituitary Adenoma
1
Gigantism
1
Gastrointestinal Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
3-Iodobenzylguanidine
8
anlotinib
4
Temozolomide
4
lutetium Lu 177 dotatate
3
Phenoxybenzamine
3
Everolimus
3
pegfilgrastim
2
cabozantinib
2
Granulocyte Colony-Stimulating Factor
2
Doxazosin
2
Dexmedetomidine
2
Capecitabine
2
Adrenalectomy
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
veliparib
1
vatalanib
1
vandetanib
1
temsirolimus
1
pentetreotide
1
penpulimab
1
pembrolizumab
1
olaparib
1
lenvatinib
1
lanreotide
1
gallium Ga 68 dotatate
1
fluorodopa F 18
1
fludarabine phosphate
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pheochromocytoma
×
lanreotide
×
Clear all
NCT03946527
2026-03-02
LAMPARA
Columbia University
Phase 2
Active not recruiting
10 enrolled